Skip to content
HomeLatest newsWhat you need to know about Johnson & Johnson’s 2022 third-quarter earnings
Image of information being disseminated

What you need to know about Johnson & Johnson’s 2022 third-quarter earnings

Check out this infographic breakdown of the company’s third-quarter 2022 performance, with key highlights from its Pharmaceutical, MedTech and Consumer Health businesses.

Inset - Quarterly Earnings Ribbon

This morning, Johnson & Johnson shared its third-quarter performance.

Since its founding in 1886, the company has grown to become one of the world’s largest and most broadly based healthcare companies, with approximately 144,000 employees across the globe working every day to help change the trajectory of health for humanity.

“The solid results delivered this quarter, including accelerated operational sales* growth in all three of our segments, reflect the strength of our business, versatility of our operations, and the unwavering commitment of Johnson & Johnson’s employees to patients and consumers around the world,” says Joe Wolk, Executive Vice President and Chief Financial Officer, Johnson & Johnson. “We invested in R&D at increased levels, advanced our pipeline and returned significant value to shareholders. Looking ahead, we will continue to execute against our long-term strategy, focused on improving health outcomes and access to care.”

For more details about the company’s 2022 third-quarter results, and to read a message from Chief Executive Officer Joaquin Duato, here’s an infographic that highlights key stats.

*Non-GAAP financial measure. Refer to the reconciliations in the full press release.


Q3 2022 Earnings infographic

Johnson & Johnson’s 2022 3rd-Quarter Earnings

Read the earnings press release, which includes full financial data for the third quarter of 2022.

Want to see more company earnings information? Find Johnson & Johnson’s past quarterly and full-year results here.

More from Johnson & Johnson

This scientist couldn’t save his father from lung cancer—but the targeted treatments Robert Zhao, Ph.D., has since developed have helped countless others

Learn more about Zhao, his partnership with Johnson & Johnson and antibody-drug conjugates—a new type of cancer therapy that targets and kills cancer cells without harming healthy cells.

After their husbands were diagnosed with multiple myeloma, these 3 care partners became health equity activists

Kimberly Alexander, Michelle Ware-Ivy and Marsha Calloway-Campbell learned firsthand that Black individuals develop multiple myeloma at higher rates. That’s why they joined Johnson & Johnson’s That’s My Word® health equity campaign, which builds awareness about the disparities surrounding this rare blood cancer.

How Johnson & Johnson is working to get medications to people around the world who need them most

In the just-released 2024 Access to Medicine Index, the company ranks among the top 5 improving access to medicines.